TY  - JOUR
T1  - Liquid biopsy in NSCLC: a new challenge in radiation therapy
A1  - Perillo, Annarita
A1  - Vincenzo, Mohamed
A1  - Olufemi, Agbaje
A1  - Robbio, Jacopo De
A1  - Roscigno, Anna
A1  - Tirozzi, Maddalena
A1  - Scognamiglio, Ida Rosalia
A1  - Margherita, Rossella
Y1  - 2021///
KW  - lung cancer
KW  - liquid biopsy
KW  - personalized therapy
KW  - radiotherapy
KW  - tissue biopsy
JF  - Exploration of Targeted Anti-tumor Therapy
SP  - 156
EP  - 173
UR  - https://www.explorationpub.com/Journals/etat/Article/100238
N2  - Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide. To date, tissue biopsy has been the gold standard for the diagnosis and the identification of specific molecular mutations, to guide choice of therapy. However, this procedure has several limitations. Liquid biopsy could represent a solution to the intrinsic limits of traditional biopsy. It can detect cancer markers such as circulating tumor DNA or RNA (ctDNA, ctRNA), and circulating tumor cells, in plasma, serum or other biological fluids. This procedure is minimally invasive, reproducible and can be used repeatedly. The main clinical applications of liquid biopsy in non-small cell lung cancer (NSCLC) patients are the early diagnosis, stratification of the risk of relapse, identification of mutations to guide application of targeted therapy and the evaluation of the minimum residual disease. In this review, the current role of liquid biopsy and associated markers in the management of NSCLC patients was analyzed, with emphasis on ctDNA and CTCs, and radiotherapy.
ER  -